Pfizer Inc.: CEO History

Pfizer supplied 90% of the penicillin used by Allied forces at D-Day — decades before it became a household brand. That 1944 wartime logistics operation was not a detour from the pharmaceutical business; it was the moment the pharmaceutical business became possible at Pfizer. The fermentation expertise developed for penicillin production became the foundation for every drug manufacturing operation that followed. One hundred seventy-five years after Charles Pfizer and Charles Erhart launched a small chemical operation in Brooklyn, the company they started generates $63.6 billion in annual revenue and employs 88,000 people across more than 125 countries. The founding capital was $2,500 — equivalent to roughly $90,000 in 2024 dollars. The market capitalization is $148 billion. That arithmetic describes a compounding machine built on a specific capability: finding molecules that modify human biology in precise, repeatable, profitable ways. The COVID-19 vaccine partnership with BioNTech produced revenues of $100.3 billion in fiscal year 2022 — a figure so anomalous it requires a second reading. Pfizer's pre-pandemic revenue was roughly $42 billion. The vaccine added $58 billion in a single year. The subsequent normalization to $63.6 billion in 2024 looks like a decline against 2022's peak but represents a genuine improvement over the pre-pandemic baseline. Understanding Pfizer without this context produces a distorted picture. Albert Bourla has led the company since 2019 through the most financially consequential period in its history. The Oncology portfolio — Ibrance, Xtandi, Eliquis — generates billions in recurring revenue. The Seagen acquisition completed in 2023 added antibody-drug conjugate technology that management has described as the foundation for the next decade of oncology growth.